tiprankstipranks
Trending News
More News >
Keymed Biosciences, Inc. (HK:2162)
:2162
Hong Kong Market

Keymed Biosciences, Inc. (2162) Stock Statistics & Valuation Metrics

Compare
1 Followers

Total Valuation

Keymed Biosciences, Inc. has a market cap or net worth of HK$12.51B. The enterprise value is HK$11.12B.
Market CapHK$12.51B
Enterprise ValueHK$11.12B

Share Statistics

Keymed Biosciences, Inc. has 279,735,570 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding279,735,570
Owned by Insiders
Owned by Institutions

Financial Efficiency

Keymed Biosciences, Inc.’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -17.86%.
Return on Equity (ROE)-0.21
Return on Assets (ROA)-0.14
Return on Invested Capital (ROIC)-17.86%
Return on Capital Employed (ROCE)-0.20
Revenue Per Employee340.32K
Profits Per Employee-409.57K
Employee Count1,258
Asset Turnover0.11
Inventory Turnover0.11

Valuation Ratios

The current PE Ratio of Keymed Biosciences, Inc. is -14.75. Keymed Biosciences, Inc.’s PEG ratio is -0.65.
PE Ratio-14.75
PS Ratio0.00
PB Ratio4.15
Price to Fair Value3.07
Price to FCF-22.78
Price to Operating Cash Flow-28.05
PEG Ratio-0.65

Income Statement

In the last 12 months, Keymed Biosciences, Inc. had revenue of 428.12M and earned -515.24M in profits. Earnings per share was -1.97.
Revenue428.12M
Gross Profit415.92M
Operating Income-618.10M
Pretax Income-508.65M
Net Income-515.24M
EBITDA-574.46M
Earnings Per Share (EPS)-1.97

Cash Flow

In the last 12 months, operating cash flow was -365.92M and capital expenditures -107.43M, giving a free cash flow of -473.35M billion.
Operating Cash Flow-365.92M
Free Cash Flow-473.35M
Free Cash Flow per Share-1.69

Dividends & Yields

Keymed Biosciences, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.33
52-Week Price Change44.58%
50-Day Moving Average43.25
200-Day Moving Average38.24
Relative Strength Index (RSI)64.77
Average Volume (3m)1.76M

Important Dates

Keymed Biosciences, Inc. upcoming earnings date is Sep 2, 2025, TBA Not Confirmed.
Last Earnings DateMar 24, 2025
Next Earnings DateSep 2, 2025
Ex-Dividend Date

Financial Position

Keymed Biosciences, Inc. as a current ratio of 3.30, with Debt / Equity ratio of 30.44%
Current Ratio3.30
Quick Ratio3.15
Debt to Market Cap0.10
Net Debt to EBITDA-0.58
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Keymed Biosciences, Inc. has paid 6.26M in taxes.
Income Tax6.26M
Effective Tax Rate-0.01

Enterprise Valuation

Keymed Biosciences, Inc. EV to EBITDA ratio is -13.82, with an EV/FCF ratio of 0.00.
EV to Sales18.54
EV to EBITDA-13.82
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00

Balance Sheet

Keymed Biosciences, Inc. has HK$2.16B in cash and marketable securities with ¥753.24M in debt, giving a net cash position of -HK$1.40B billion.
Cash & Marketable SecuritiesHK$2.16B
Total Debt¥753.24M
Net Cash-HK$1.40B
Net Cash Per Share-HK$5.01
Tangible Book Value Per ShareHK$9.41

Margins

Gross margin is 97.15%, with operating margin of -144.37%, and net profit margin of -120.35%.
Gross Margin97.15%
Operating Margin-144.37%
Pretax Margin-118.81%
Net Profit Margin-120.35%
EBITDA Margin-134.18%
EBIT Margin-146.24%

Analyst Forecast

The average price target for Keymed Biosciences, Inc. is HK$60.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$60.00
Price Target Upside20.97% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast16.35%
EPS Growth Forecast-49.63%

Scores

Smart Score7
AI Score52
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis